Difelikefalin (pruritus in patients with chronic kidney disease who are on hemodialysis)



  • Active Substance: Difelikefalin
  • Name: Kapruvia®
  • Therapeutic area: Pruritus
  • Pharmaceutical company: Fresenius Medical Care Nephrologica Deutschland GmbH


Time table:

  • Start: 01.10.2022
  • Publication of assessment: 02.01.2023
  • End of public hearing: 23.01.2023
  • Final decision by G-BA: middle of March 2023


Comparative therapy:

  • A patient-individual therapy taking into account prior therapies and the severity of symptoms